Med-advise Consulting Competitors and Similar CompaniesClear all

Med-advise Consulting's competitors and similar companies include Commercial Eyes, HTA Consulting, AUSTAR Group and Daewoong Pharmaceutical.

	Med-advise Consulting Med-Advise Consulting is a company that provides healthcare and medical consultation services.	Commercial Eyes Commercial Eyes is a company that provides pharmaceutical and medical device consulting services.	HTA Consulting HTA Consulting is a company that provides health technology assessment for drugs, medical devices, and diagnostic methods.	AUSTAR Group AUSTAR Group (also known AUSTAR Lifesciences) is a technology-based pharmaceutical engineering solution provider.	Daewoong Pharmaceutical Daewoong Pharmaceutical (대웅제약) is a company that provides pharmaceutical solutions and services.
Founding Date	Founding Date 2006	Founding Date 2001	Founding Date 2001	Founding Date 1991	Founding Date 2002
Type	Type Private	Type Private	Type Private	Type Public	Type Public
Tags	Tags Healthcare management consulting medical devices pharma	Tags Healthcare management consulting medical devices pharma	Tags Healthcare management consulting medical devices pharma	Tags Healthcare medical devices pharma	Tags Healthcare drug development medical devices pharma
Locations	Locations Scottsdale, US HQ	Locations Melbourne, AU HQ	Locations Kraków, PL HQ	Locations CN HQ	Locations Seoul, KR HQ Hyderabad, IN Taguig City, PH Bangkok, TH
Employees	Employees 2	Employees 795% decrease	Employees 442% increase	Employees 1,445	Employees 1,669
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) ¥1.5b (FY, 2025)	Revenue (est.) ₩2.1t (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods ¥1.2b (FY, 2025)	Cost of goods (₩2b) (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit ¥354.8m (FY, 2025)	Gross profit ₩2.1t (FY, 2025)
Net income	Net income N/A	Net income N/A	Net income N/A	Net income ¥32.9m (FY, 2025)	Net income ₩227.9b (FY, 2025)